GLP-1 drugs enter psychiatry, curbing antipsychotic weight gain while raising new questions about addiction, mood, eating disorders, and culture.
|Slideshows|August 29, 2017
6 Signs Your Patient Is at Risk for Treatment-Resistant Depression
What factors predispose patients to TRD and what treatment strategies achieve response? Find out here, with a bonus case vignette.
Advertisement
Advertisement
Related to this article
Alkermes launches a phase 2 trial of oral orexin-2 agonist ALKS 7290 to boost antidepressant response in major depressive disorder, assessing safety and symptom relief.
A systematic review and meta-analysis compares pharmacological agents with nonpharmacologic approaches to identify the most effective interventions for insomnia in peri- and postmenopausal women.
The evidence points toward an overall protective effect in adult cohorts and no increase in completed suicide in younger populations.
This study compared the efficacy and tolerability of the 5 second-generation antipsychotics that are currently FDA approved as adjunctive treatments for adults with MDD.
Ketamine or esketamine during C-section anesthesia lowers early postpartum depression symptom scores in trials, hinting at a new prevention approach under study.
Real-world data show TRD costs spike during resistant episodes; Compass’ psilocybin COMP360 delivers durable symptom relief through 26 weeks, potentially easing resource strain.
Advertisement
Advertisement
Trending on Psychiatric Times
1
The Ozempic Dilemma: Promises and Pitfalls in Psychiatry
2
Schizophrenia: A Telltale of the Brain’s Complexity
3
Talking With Titans: Sheldon Preskorn, MD, on the Evolution of Psychopharmacology
4
Podcast: Interventional Psychiatry and the Challenge of Difficult-to-Treat Depression
5